Recent News

• 11.28.2025 - TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
• 11.19.2025 - TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
• 11.10.2025 - TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
• 11.03.2025 - TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
• 10.31.2025 - TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
• 10.28.2025 - TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
• 09.24.2025 - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
• 09.24.2025 - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
• 09.24.2025 - New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
• 09.10.2025 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Recent Filings

• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 144 Report of proposed sale of securities
• 11.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 8-K Current report
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 144 Report of proposed sale of securities